With many people on holiday right now, it’s good time to take stock of 2026 so far and look ahead to the rest of the year. The first half of 2026 has been really strong. The XBI index gained 23% and – more pertinently for privately-held biotechs – there was huge amounts of M&A going on. From January to June there were 33 deals worth more than $1 billion – according to Drug Discovery News – including three […]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]
Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282 Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops […]
